Navigation Links
Arrayit on Major Fundraising Drive
Date:9/9/2013

SUNNYVALE, Calif., Sept. 9, 2013 /PRNewswire/ -- Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) has been approached, through their financial advisor, who is a major shareholder in the company, by an overseas bank, and 3 mid-level investment banking houses, to help Arrayit raise up to $10 million in funds, either through a secured loan, or a convertible bond issue, with the conversion above 100% of the current stock price.

Discussions are in preliminary stages, terms have not been agreed to, and there can be no assurance that anything will become of the negotiations. ARYC expects to have something more definitive within the next 3 weeks.

About Arrayit Corporation                           

Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company's innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit's products are used by nearly every major research center in the world.

About Liston Street Pulse                                                

Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Subscribe here to read more about ARYC, including CEO interviews.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and Form 10-Q for the fiscal first quarter ended March 31, 2013, Form 10-Q for the fiscal second quarter ended June 30, 2013.

http://www.arrayit.com 
http://www.Listonstreetpulse.com


'/>"/>
SOURCE Arrayit Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arrayit Corporation Holds Successful Meeting with DHK Medical Products CEO
2. Actor Lee Majors Joins Flu + You Campaign to Raise Awareness of Risks of Flu for People 65 and Older
3. Summit Brings Major Non-Profits, Venture, Pharma and Academics Together
4. Roche/Chugais Bitopertin Will Garner Nearly $1.5 Billion in Major-Market Sales in 2022 as the First Approved Treatment for Negative Symptoms in Schizophrenia
5. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
6. Majority of Springfield Voters Oppose Prescription Only PSE Requirements
7. Market Access Trends Report Outlines Eleven Major Trends Impacting The U.S. Healthcare System
8. Parent Project Muscular Dystrophy Returns to Baltimore for Annual Connect Conference; Presenters Include FDA, Major Pharma
9. Major League Baseball Charities and The Partnership at Drugfree.org Announce the Fourth Annual Commissioners Play Healthy Awards
10. Catalent Pharma Solutions Breaks Ground On A Major Expansion Of Its Winchester, Kentucky Controlled Release Manufacturing Facility
11. Patient and Healthcare Worker Safety Major Areas of Focus at B.Braun
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... and EDMONTON, Alberta , ... scientists and the University of Alberta in ... data in Nature,s partner journal, Schizophrenia 1 , ... predict instances of schizophrenia with 74% accuracy. This ... severity of specific symptoms in schizophrenia patients with ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 billion in ... brand medicines, generics and the supply chain account for 14 percent ... of this (7 percent)? Or that the United States ... investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry accounts ...
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... ... effectively destroyed the construction site and threatened numerous homes and businesses nearby, causing ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, Inc. ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Axiad ... organizations, today announced it has partnered with WALLIX to expand its solution ... 800-171 . , There are a number of ways to address the authentication requirements ...
(Date:7/24/2017)... ... 24, 2017 , ... Puregraft, the global leader in the ... United States Patent Number 9,695,398 (the '398 patent) and South Korean Patent Number ... '324 patents cover methods and systems for optimizing fat grafts for current and ...
(Date:7/24/2017)... ... 2017 , ... A new report released today by FusionHealth, ... health care at scale, indicates record-breaking adherence results for the company’s obstructive sleep ... pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range between ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating ... enrolled over 100,000 children in their treatment program. Clubfoot is a pervasive problem ... where treatment is limited or non-existent. Without intervention, these children are destined to ...
Breaking Medicine News(10 mins):